Form 8-K - Current report:
SEC Accession No. 0001558370-25-006106
Filing Date
2025-05-01
Accepted
2025-05-01 16:15:24
Documents
16
Period of Report
2025-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nxtc-20250501x8k.htm   iXBRL 8-K 48306
2 EX-99.1 nxtc-20250501xex99d1.htm EX-99.1 72706
3 GRAPHIC nxtc-20250501xex99d1001.jpg GRAPHIC 6649
  Complete submission text file 0001558370-25-006106.txt   267246

Data Files

Seq Description Document Type Size
4 EX-101.SCH nxtc-20250501.xsd EX-101.SCH 4100
5 EX-101.DEF nxtc-20250501_def.xml EX-101.DEF 2849
6 EX-101.LAB nxtc-20250501_lab.xml EX-101.LAB 17253
7 EX-101.PRE nxtc-20250501_pre.xml EX-101.PRE 11363
18 EXTRACTED XBRL INSTANCE DOCUMENT nxtc-20250501x8k_htm.xml XML 4801
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38905 | Film No.: 25903307
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)